369 related articles for article (PubMed ID: 26791735)
1. [Hyperuricemia. When and how to treat?].
Reuss-Borst MA
Internist (Berl); 2016 Feb; 57(2):194-201. PubMed ID: 26791735
[TBL] [Abstract][Full Text] [Related]
2. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
[TBL] [Abstract][Full Text] [Related]
3. Update on gout and hyperuricemia.
Baker JF; Schumacher HR
Int J Clin Pract; 2010 Feb; 64(3):371-7. PubMed ID: 19909378
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of hyperuricemia and gout based on the guideline for the management of hyperuricemia and gout].
Taniguchi A
Nihon Yakurigaku Zasshi; 2010 Dec; 136(6):330-4. PubMed ID: 21139283
[No Abstract] [Full Text] [Related]
5. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
6. [Hyperuricemia and gout : New aspects of an old disease].
Witt M; Schulze-Koops H
Internist (Berl); 2016 Jul; 57(7):656-65. PubMed ID: 27286837
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat for the chronic management of hyperuricemia in patients with gout.
Chinchilla SP; Urionaguena I; Perez-Ruiz F
Expert Rev Clin Pharmacol; 2016; 9(5):665-73. PubMed ID: 26942273
[TBL] [Abstract][Full Text] [Related]
8. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
Med Lett Drugs Ther; 2017 Nov; 59(1533):182-183. PubMed ID: 29125593
[No Abstract] [Full Text] [Related]
9. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
10. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
11. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
Chao J; Terkeltaub R
Curr Rheumatol Rep; 2009 Apr; 11(2):135-40. PubMed ID: 19296886
[TBL] [Abstract][Full Text] [Related]
12. Management of Gout and Hyperuricemia in CKD.
Vargas-Santos AB; Neogi T
Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
[TBL] [Abstract][Full Text] [Related]
13. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
[TBL] [Abstract][Full Text] [Related]
14. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
15. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of hyperuricemia and gout].
Gröbner W; Walter-Sack I
Med Monatsschr Pharm; 2005 May; 28(5):159-64; quiz 165-6. PubMed ID: 15912988
[No Abstract] [Full Text] [Related]
17. [Uricosuric agent].
Ohno I
Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
[TBL] [Abstract][Full Text] [Related]
18. Urate-lowering therapy for gout: focus on febuxostat.
Love BL; Barrons R; Veverka A; Snider KM
Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
[TBL] [Abstract][Full Text] [Related]
19. Progress in the pharmacotherapy of gout.
Sundy JS
Curr Opin Rheumatol; 2010 Mar; 22(2):188-93. PubMed ID: 20110792
[TBL] [Abstract][Full Text] [Related]
20. Febuxostat: a new treatment for hyperuricaemia in gout.
Edwards NL
Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
